Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

Unlike normal B cells, and similar to fat cells, chronic lymphocytic leukemia (CLL) cells aberrantly express lipoprotein lipase (LPL), which contributes to free fatty acids (FFAs) metabolism. Here we show that, in CLL cells, the B cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Main Authors: Rozovski, Uri, Harris, David M., Li, Ping, Liu, Zhiming, Jain, Preetesh, Ferrajoli, Alessandra, Burger, Jan, Thompson, Phillip, Jain, Nitin, Wierda, William, Keating, Michael J., Estrov, Zeev
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135679/
https://ncbi.nlm.nih.gov/pubmed/29465264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1439167
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares